{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:47:30Z","timestamp":1768463250522,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00228-024-03711-8","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T10:01:36Z","timestamp":1718964096000},"page":"1399-1407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Population pharmacokinetics of free and liposome-encapsulated mitoxantrone in patients with relapsed\/refractory lymphoma or small cell lung cancer"],"prefix":"10.1007","volume":"80","author":[{"given":"Gaoqi","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dihong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Like","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiufang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhufeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiu","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"issue":"2","key":"3711_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.ejpb.2008.05.019","volume":"70","author":"C Li","year":"2008","unstructured":"Li C, Cui J, Wang C, Li Y, Zhang H, Wang J, Li Y, Zhang L, Zhang L, Guo W, Wang Y (2008) Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy. Eur J Pharm Biopharm 70(2):657\u2013665. https:\/\/doi.org\/10.1016\/j.ejpb.2008.05.019","journal-title":"Eur J Pharm Biopharm"},{"issue":"1\u20132","key":"3711_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ijpharm.2013.10.023","volume":"460","author":"C Li","year":"2014","unstructured":"Li C, Zhao X, Deng C, Wang C, Wei N, Cui J (2014) Pegylated liposomal mitoxantrone is more therapeutically active than mitoxantrone in L1210 ascitic tumor and exhibits dose-dependent activity saturation effect. Int J Parm 460(1\u20132):165\u2013172. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.10.023","journal-title":"Int J Parm"},{"issue":"Suppl 4","key":"3711_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2165\/00003495-199700544-00004","volume":"54","author":"TM Allen","year":"1997","unstructured":"Allen TM (1997) Liposomes. Opportunities in drug delivery. Drugs 54(Suppl 4):8\u201314. https:\/\/doi.org\/10.2165\/00003495-199700544-00004","journal-title":"Drugs"},{"issue":"1","key":"3711_CR4","first-page":"566","volume":"281","author":"HJ Lim","year":"1997","unstructured":"Lim HJ, Masin D, Madden TD, Bally MB (1997) Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacol Exp Ther 281(1):566\u2013573","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"3711_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2174\/138920012798356934","volume":"13","author":"P Milla","year":"2012","unstructured":"Milla P, Dosio F, Cattel L (2012) PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab 13(1):105\u2013119. https:\/\/doi.org\/10.2174\/138920012798356934","journal-title":"Curr Drug Metab"},{"issue":"12","key":"3711_CR6","first-page":"1565","volume":"45","author":"CX Wang","year":"2010","unstructured":"Wang CX, Li CL, Zhao X, Yang HY, Wei N, Li YH, Zhang L, Zhang L (2010) Pharmacodynamics, pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride. Yao Xue Xue Bao 45(12):1565\u20131569","journal-title":"Yao Xue Xue Bao"},{"issue":"3","key":"3711_CR7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00280-014-2523-8","volume":"74","author":"J Yang","year":"2014","unstructured":"Yang J, Shi Y, Li C, Gui L, Zhao X, Liu P, Han X, Song Y, Li N, Du P, Zhang S (2014) Phase I clinical trial of pegylated liposomal mitoxantrone PLM-s: pharmacokinetics, toxicity and preliminary efficacy. Cancer Chemother Pharmacol 74(3):637\u2013646. https:\/\/doi.org\/10.1007\/s00280-014-2523-8","journal-title":"Cancer Chemother Pharmacol"},{"key":"3711_CR8","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1182\/blood-2023-188430","volume":"142","author":"Q Cai","year":"2023","unstructured":"Cai Q, Xia Y, Wang L, Huang H, Wang J, Cai J, Tian X (2023) Combination of mitoxantrone hydrochloride liposome with tislelizumab in patients with relapsed or refractory NK\/T cell lymphoma: a phase Ib\/II clinical trial. Blood 142:4470. https:\/\/doi.org\/10.1182\/blood-2023-188430","journal-title":"Blood"},{"issue":"5","key":"3711_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2165\/00003495-199856050-00001","volume":"56","author":"TM Allen","year":"1998","unstructured":"Allen TM (1998) Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 56(5):747\u2013756. https:\/\/doi.org\/10.2165\/00003495-199856050-00001","journal-title":"Drugs"},{"issue":"6","key":"3711_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1517\/17425255.2011.570330","volume":"7","author":"M Morotti","year":"2011","unstructured":"Morotti M, Valenzano Menada M, Venturini PL, Ferrero S (2011) Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment. Expert Opin Drug Metab Toxicol 7(6):707\u2013720. https:\/\/doi.org\/10.1517\/17425255.2011.570330","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"3711_CR11","doi-asserted-by":"publisher","first-page":"6615","DOI":"10.3390\/ijms24076615","volume":"24","author":"MD Fulton","year":"2023","unstructured":"Fulton MD, Najahi-Missaoui W (2023) Liposomes in cancer therapy: how did we start and where are we now. Int J Mol Sci 24(7):6615. https:\/\/doi.org\/10.3390\/ijms24076615","journal-title":"Int J Mol Sci"},{"key":"3711_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.35248\/2167-7700.23.11.175","volume":"11","author":"Y Hu","year":"2023","unstructured":"Hu Y, Ouyang W, Zhang J, Chen M, Qing D, Zeng Q, Huang Y, Hao C, Jia R, Wu Z, Ni S, Huang Y (2023) Pharmacokinetics, safety profiles and efficacy of liposomal mitoxantrone hydrochloride in patients with relapse\/refractory advanced lymphoma. Chemo Open Access 11:175. https:\/\/doi.org\/10.35248\/2167-7700.23.11.175","journal-title":"Chemo Open Access"},{"issue":"4","key":"3711_CR13","first-page":"1879","volume":"45","author":"DS Alberts","year":"1985","unstructured":"Alberts DS, Peng YM, Leigh S, Davis TP, Woodward DL (1985) Disposition of mitoxantrone in cancer patients. Cancer Res 45(4):1879\u20131884","journal-title":"Cancer Res"},{"issue":"9","key":"3711_CR14","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/psp4.12838","volume":"11","author":"RJ Svensson","year":"2022","unstructured":"Svensson RJ, Jonsson EN (2022) Efficient and relevant stepwise covariate model building for pharmacometrics. CPT Pharmacometrics Syst Pharmacol 11(9):1210\u20131222. https:\/\/doi.org\/10.1002\/psp4.12838","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"3711_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/psp4.12790","volume":"11","author":"EN Jonsson","year":"2022","unstructured":"Jonsson EN, Nyberg J (2022) A quantitative approach to the choice of number of samples for percentile estimation in bootstrap and visual predictive check analyses. CPT Pharmacometrics Syst Pharmacol 11(6):673\u2013686. https:\/\/doi.org\/10.1002\/psp4.12790","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"3711_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","volume":"35","author":"TM Post","year":"2008","unstructured":"Post TM, Freijer JI, Ploeger BA, Danhof M (2008) Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 35(2):185\u2013202. https:\/\/doi.org\/10.1007\/s10928-007-9081-1","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"3711_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/a:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481\u2013504. https:\/\/doi.org\/10.1023\/a:1012299115260","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"3711_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF00174156","volume":"3","author":"DS Alberts","year":"1985","unstructured":"Alberts DS, Peng YM, Bowden GT, Dalton WS, Mackel C (1985) Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 3(2):101\u2013107. https:\/\/doi.org\/10.1007\/BF00174156","journal-title":"Invest New Drugs"},{"issue":"3","key":"3711_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/bjc.1992.81","volume":"65","author":"B Richard","year":"1992","unstructured":"Richard B, Launay-Iliadis MC, Iliadis A, Just-Landi S, Blaise D, Stoppa AM, Viens P, Gaspard MH, Maraninchi D, Cano JP (1992) Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation. Br J Cancer 65(3):399\u2013404. https:\/\/doi.org\/10.1038\/bjc.1992.81","journal-title":"Br J Cancer"},{"issue":"10","key":"3711_CR20","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/jps.2600781020","volume":"78","author":"MC Launay","year":"1989","unstructured":"Launay MC, Iliadis A, Richard B (1989) Population pharmacokinetics of mitoxantrone performed by a NONMEM method. J Pharm Sci 78(10):877\u2013880. https:\/\/doi.org\/10.1002\/jps.2600781020","journal-title":"J Pharm Sci"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03711-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03711-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03711-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T07:05:05Z","timestamp":1722927905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03711-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["3711"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03711-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Ethics Committee of the Guizhou Medical University and West China Hospital of Sichuan University. The patients provided their written informed consent to participate in both studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors read and approved the final manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}